When mice with osteolytic sarcoma or osteosarcoma were treated with OPG or RANK-Fc (a recombinant RANKL antagonist), resulting in a decrease in osteoclast numbers, protection against tumor-induced lytic bone lesions was observed (Figure 1C–G) [45,64,68]. Here, TNFRSF11A is linked to neoplasm.